Micromet, Inc. (NASDAQ: MITI)
2110 Rutherford Road
Carlsbad, CA 92008
Phone: (760) 494-4200
Micromet, Inc. (NASDAQ: MITI) is a biotechnology company focused on the research and development of novel biological products for the treatment and control of cancer, inflammation and autoimmune diseases. All of these indication areas are characterized by significant unmet medical needs.
Using its antibody technology platforms, Micromet´s goal is to create novel drugs that are highly specific, effective and well tolerated in patients. The Company currently has four candidates, adecatumumab (MT201), MT293 (TRC093), MT110 and blinatumomab (MT103), in clinical trials against major cancer indications, including metastatic breast cancer and relapsed non-Hodgkin's lymphoma (NHL). In addition, Micromet´s pipeline includes a number of preclinical drug candidates and several compounds at research stage. The Company has strategic collaborations or license agreements with Bayer-Schering, Sanofi-aventis, MedImmune, Merck Serono, Morphotek, Nycomed and TRACON Pharmaceuticals.
Christian Itin, PhD, President, Chief Executive Officer and Director
Barclay Phillips, Senior Vice President and Chief Financial Officer
Patrick A. Baeuerle, PhD, Professor for Immunology, Senior Vice President and Chief Scientific Officer
Jan Fagerberg, M.D., Senior Vice President and Chief Medical Officer
Jens Hennecke, PhD, Senior Vice President Business Development
Mark Reisenauer, Senior Vice President and Chief Commercial Officer
Matthias Alder, LL.M, Senior Vice President, General Counsel and Secretary
Presentation & Webcast Archive:
BiTE Antibody Platform:
68,985,005 Outstanding as of Nov 2, 2009
Need updated info here
Contact Information Investors:
Ines-Regina Buth (760) 494-4235 (US) +49 (0)89 895277 221 (Europe) email@example.com
Media Europe: Evelyn Wolf +49 (0)89 895277 220 firstname.lastname@example.org
Media US: Susan Noonan (212) 966-3650 email@example.com
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp